Search results
Colon cancer: Symptoms, causes and treatment
Daily Telegraph· 7 days agoMore than 50 per cent of cases are preventable, and if it’s caught early, survival rates are promising for this common type of cancer
National Cancer Survivors Day: Celebrating Strength, Inspiring Hope, And Highlighting Advances In ...
Black Enterprise· 4 days agoJune 2 is National Cancer Survivors Day (NCSD). The day is a poignant reminder of the progress made...
Colorectal cancer: Immunotherapy drug may help patients avoid surgery
Medical News Today· 14 hours agoPast research shows that treating MMR deficient/MSI-High colorectal cancer tumors can sometimes be...
National Cancer Survivors Day is a celebration of life
Rolling Out· 4 days agoJune 2 marks a significant occasion for many individuals and families across the globe—it's National...
Immunotherapy drug may keep colon cancer patients cancer-free after surgery
UPI· 3 days agoDoctors in Britain say that an immunotherapy drug, given before surgery, can help many more colon ...
Alonzo Mourning Beats Prostate Cancer, Encourages Men to Get Checked
Heavy.com· 4 days agoMourning was diagnosed with Stage 3 prostate cancer, undergoing a procedure in the middle of March,...
TikTok influencers claim sunscreen is harmful. Here's why that's wrong, and dangerous
Daytona Beach News-Journal via Yahoo News· 19 hours agoBlack patients with melanoma have an estimated five-year melanoma survival rate of 70 percent,...
'Artificial lymph node' used to treat cancer in mice
Medical Xpress· 13 hours ago"They are a landing spot where T-cells, the immune system's fighting cells, lay dormant, waiting to be activated to fight infections or other abnormal cells," says Natalie Livingston, Ph.D., ...
HOFer Mourning recovering from prostate cancer
ESPN· 4 days agoNaismith Basketball Hall of Fame center Alonzo Mourning underwent surgery to remove his prostate after a diagnosis of Stage 3 prostate cancer, Mourning...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoGenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024
